Crossmark

The effects of reimbursement reform of antidiabetic medicines from the patients’ perspective – a survey among patients with type 2 diabetes in Finland

Crossref DOI link: https://doi.org/10.1186/s12913-019-4633-9

Published Online: 2019-10-29

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Suviranta, Taika

Timonen, Johanna

Martikainen, Janne

Aarnio, Emma https://orcid.org/0000-0002-6555-7833
Funding

Funding for this research was provided by:

The Social Insurance Institution of Finland (32/26/2017)
License Information

Text and Data Mining valid from 2019-10-29

Version of Record valid from 2019-10-29
More Information

Article History

Received: 20 June 2019

Accepted: 14 October 2019

First Online: 29 October 2019

Ethics approval and consent to participate

: The study complied with the national ethical principles of research. According to instructions, this study did not require ethical approval. Participation in the study was voluntary and answering was regarded as an informed consent to participate in the survey.

: Not applicable.

: JM is a senior partner of ESiOR Oy, which performs studies and health economic evaluations for several pharmaceutical companies, food industry companies, medical device companies, hospitals, and academic institutions. JM, JT, and EA have received research grants from the Social Insurance Institution of Finland. EA has also received funding form the Finnish Cultural Foundation. TS declares to have no competing interests.

Document is current

Any future updates will be listed below